Начало・Списък с акции・Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals Inc

Отворен

СекторЗдравеопазване

3.44 1.18

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.32

Максимум

3.51

Ключови измерители
By Trading Economics
Приходи	-5.1M -48M
EPS	-0.42
Служители	202
EBITDA	-8M -45M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+246.04% upside

Дивиденти
By Acuity
Следващи печалби	5.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-39M 355M
Предишно отваряне	2.26
Предишно затваряне	3.44

Настроения в новините

By Acuity

15%

85%

25 / 340 Класиране в Healthcare

Rocket Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.08.2026 г., 22:01 ч. UTC

Event

Rocket Pharmaceuticals shares are lower in after-market trading despite a positive clinical safety update on its Phase 2 trial for RP-A501.

31.07.2026 г., 22:01 ч. UTC

Rocket Pharmaceuticals shares declined in after-hours trading, continuing a downward trend since Friday's close. The stock remains below its 20-day moving average.

30.07.2026 г., 21:51 ч. UTC

Rocket Pharmaceuticals is lower in after-market hours, reflecting declines in the Biotechnology sub-sector. The stock remains below its 20-day moving average.

29.07.2026 г., 20:52 ч. UTC

Rocket Pharmaceuticals shares are lower in after-market hours amid a broader market decline driven by rising crude oil prices and geopolitical tensions.

28.07.2026 г., 19:22 ч. UTC

Rocket Pharmaceuticals Inc is trading lower today, reflecting broader market trends. The stock remains below its 20-day moving average and near its one-month trading range low.

27.07.2026 г., 16:16 ч. UTC

Rocket Pharmaceuticals is trading higher today, recovering from an earlier dip. Broader market volatility follows a notable decline in oil prices amid geopolitical developments.

24.07.2026 г., 19:06 ч. UTC

Rocket Pharmaceuticals is trading lower, extending a five-session decline. Broader market pressures and falling crude oil prices are influencing investor sentiment.

22.07.2026 г., 20:06 ч. UTC

Rocket Pharmaceuticals shares are lower, marking four consecutive sessions of declines. The stock has closed below its 20-day moving average.

20.07.2026 г., 19:46 ч. UTC

News

Rocket Pharmaceuticals shares are higher today amid mixed analyst sentiments, with Wall Street Zen downgrading to "sell" and Chardan Capital maintaining a "buy" rating.

Сравнение с други в отрасъла

Ценова промяна

Rocket Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

246.04% нагоре

12-месечна прогноза

Среден 11.8 USD 246.04%

Висок 16 USD

Нисък 10 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за Rocket Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

7 ratings

Купи

Задържане

Продай

Според 7 анализатори, дали борсови рейтинги на Rocket Pharmaceuticals Inc през последните 3 месеца.

Настроение

By Acuity

25 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.